The Valley Desk

Clinical trial reportThe Journal of rheumatologyPublished

Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
The Journal of rheumatology
Published
Subject terms
Humans; Arthritis, Psoriatic; Antirheumatic Agents; Treatment Outcome; Double-Blind Method; Antibodies, Monoclonal, Humanized; Tumor Necrosis Factor Inhibitors; Safety; Adverse effects; Psoriatic Arthritis; Biologic Therapy; Guselkumab
PubMed ID
36642439
Added to directory
Source checked

Report a correction or request removal